Preventing Acquired Resistance to Bedaquiline and Delamanid in Multidrug-Resistant Tuberculosis Treatment Requires Optimal Management

Am J Respir Crit Care Med. 2016 Nov 1;194(9):1170-1171. doi: 10.1164/rccm.201604-0841LE.

Authors

Lorenzo Guglielmetti^{1

2

3}, Damien Le Dû¹, Mathilde Fréchet-Jachym¹, Carole Mitnick^{4

5

6}

Affiliations

¹ 1 Centre Hospitalier de Bligny Briis-sous-Forges, France.
² 2 Pierre and Marie Curie University Paris, France.
³ 3 INSERM U1135 Paris, France.
⁴ 4 Harvard Medical School Boston, Massachusetts.
⁵ 5 Partners in Health Boston, Massachusetts and.
⁶ 6 Brigham and Women's Hospital Boston, Massachusetts.

PMID: 27797614
DOI: 10.1164/rccm.201604-0841LE

No abstract available

Publication types

Comment

MeSH terms

Antitubercular Agents
Diarylquinolines*
Humans
Tuberculosis, Multidrug-Resistant*

Substances

Antitubercular Agents
Diarylquinolines
bedaquiline